Boehringer Ingelheim, LEO Pharma collaborate to commercialize, further develop Spevigo

SPEVIGO is a humanized and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor - a key signaling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, including generalized pustular psoriasis (GPP).

This partnership extends beyond GPP, with an opportunity to investigate the potential of spesolimab in additional skin conditions with high unmet medical need in which IL-36 is implicated.

Under the terms of the agreement, LEO Pharma will be responsible for commercialization and further development of SPEVIGO leveraging its global commercial platform within medical dermatology to raise disease awareness and secure access for patients with GPP. The addition of Boehringer Ingelheim’s flagship dermatology product, SPEVIGO, for the treatment of GPP, complements LEO Pharma’s existing strategic dermatology portfolio and reinforces its long-standing commitment to delivering transformational medicines to patients.

“We are immensely proud of what SPEVIGO represents for people living with GPP and bringing innovation to this community of patients has been a powerful reflection of our purpose to transform lives,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “SPEVIGO holds a significant promise, and ensuring it reaches its full potential requires continued focus, and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we’ve laid. We remain profoundly grateful to the patients, caregivers, and healthcare professionals who have walked this journey with us.”

“Skin diseases can profoundly impact people’s lives - and at LEO Pharma, we are here to change that,” said Christophe Bourdon, CEO of LEO Pharma. “Partnering to bring SPEVIGO to more patients is more than a strategic step - it means the opportunity to help people living with GPP by addressing a disease with limited treatment options and aiming to improve their quality of life. We are inspired by Boehringer Ingelheim’s pioneering efforts and thrilled to build on that foundation. Together, we have a powerful opportunity to expand access to innovative care and deliver meaningful progress for patients who have long been underserved.”

GPP is a rare, heterogeneous, and potentially life-threatening skin disease. It is characterized by the accumulation of neutrophils (a type of white blood cell) in the skin, leading to painful, sterile pustules across the body. The disease course varies, with some patients experiencing relapsing episodes with recurrent flares - often accompanied by fever, malaise, fatigue, and a risk of organ failure - while others endure persistent disease with intermittent flares.

SPEVIGO is available in more than 40 countries including the U.S., Japan, China, and most European countries to treat GPP flares in adults. It is an approved treatment for GPP flares that specifically targets the IL-36 pathway and that has been evaluated in a statistically powered, randomized, placebo-controlled trial. Additionally, SPEVIGO has also been approved for expanded indications in generalized pustular psoriasis in the EU, U.S. and China. SPEVIGO is also under investigation for the treatment of other IL-36 mediated skin diseases.

The transaction is anticipated to close in the second half of 2025, subject to merger control clearance, with Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.